Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Oct;18(4):3571-3580.
doi: 10.3892/ol.2019.10689. Epub 2019 Jul 30.

Correlation analysis of expression and prognosis of TTF-1 and CD44v6 in undifferentiated lung carcinoma

Yudong Wu  1 , Xia Yu  1 , Mingzhu Liang  2 , Baojun Wang  3
Affiliations

Correlation analysis of expression and prognosis of TTF-1 and CD44v6 in undifferentiated lung carcinoma

Yudong Wu et al. Oncol Lett. 2019 Oct.

Abstract

The correlation between expression and prognosis of thyroid transcription factor-1 (TTF-1) and CD44v6 in undifferentiated lung carcinoma was investigated. There were 116 cases with large cell undifferentiated carcinoma in group A, 120 cases with small cell undifferentiated carcinoma in group B and 80 normal individuals from the same period in group C. The expression levels of TTF-1 and CD44v6 in the serum of group A, B and C and the cancer tissues and adjacent tissues of group A, B and C were detected using enzyme-linked immunosorbent assay (ELISA), and the levels in each group were compared. Pearsons test was used to analyze the correlation between TTF-1 and CD44v6 expression in serum of group A and group B and cancer tissues. Patients were divided into the survival group and the deceased group according to their 5-year survival. Multivariate logistic regression was applied to analyze the risk factors of mortality, and receiver operating characteristic curve (ROC) was used to analyze the diagnostic value of TTF-1 and CD44v6. The best cut-off values of TTF-1 and CD44v6 were divided into the high and low expression groups to observe the 5-year mortality of patients and the Kaplan-Meier (K-M) survival curve was drawn. Multivariate logistic regression was used to analyze the risk factors of mortality. The expression of CD44v6 in the serum of group A and group B was higher than that in group C, and that of group B was higher than that in group A (P<0.05). The expression of TTF-1 in serum of group A and group B was higher than that of group C, and the expression of TTF-1 in group A was higher than that in group B (P<0.05). The expression of TTF-1 and CD44v6 in group A and group B were significantly higher than those in adjacent tissues (P<0.05). The expression of TTF-1 in group A was higher than that in group B (P<0.05), and that of CD44v6 was lower than that in group B (P<0.05). The 5-year survival of patients showed that 209 patients died and 27 survived at 5 years; the survival rate was 11.44%. The course of disease, TNM stage, TTF-1 and CD44v6 were independent mortality factors for undifferentiated lung cancer.

Keywords: CD44v6; TTF-1; large cell undifferentiated carcinoma; small cell undifferentiated carcinoma; undifferentiated lung carcinoma.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Correlation between the expression of TTF-1 and CD44v6 in serum of group A and group B and cancer tissues. (A) The expression of TTF-1 in serum of group A was positively correlated with the expression of TTF-1 in cancer tissues (r=0.701, P<0.001). (B) The expression of CD44v6 in serum of group A was positively correlated with the expression of CD44v6 in cancer tissues (r=0.714, P<0.001). (C) The expression of TTF-1 in serum of group B was positively correlated with the expression of TTF-1 in cancer tissues (r=0.660, P<0.001). (D) The expression of CD44v6 in serum of group B was positively correlated with the expression of CD44v6 in cancer tissues (r=0.767, P<0.001).
Figure 2.
Figure 2.
ROC curve of TTF-1 and CD44v6 in diagnosis of undifferentiated lung cancer. TTF-1 AUC was 0.852, 95% CI, 0.812–0.893; CD44v6 AUC was 0.840, 95% CI, 0.797–0.883, and the combined detection of AUC was 0.934, 95% CI, 0.908–0.960.
Figure 3.
Figure 3.
ROC curves of TTF-1 and CD44v6 in the diagnosis of large and small cell cancers. TTF-1 AUC was 0.766, 95% CI, 0.702–0.831; CD44v6 AUC was 0.715, 95% CI, 0.649–0.780, and combined detection AUC was 0.820, 95% CI, 0.766–0.875.
Figure 4.
Figure 4.
Five-year survival of patients. The 5-year survival rate was 11.44%.
Figure 5.
Figure 5.
ROC curve of TTF-1 and CD44v6 in undifferentiated lung cancer mortality. TTF-1 AUC was 0.866, 95% CI, 0.820–0.912; CD44v6 AUC was 0.746, 95% CI, 0.684–0.808, and the combined detection of AUC was 0.897, 95% CI, 0.857–0.936.
Figure 6.
Figure 6.
Correlation between TTF-1 expression and 5-year survival of patients. The 5-year survival of patients with high TTF-1 expression was significantly lower than that of patients with low TTF-1 expression (P<0.001).
Figure 7.
Figure 7.
Correlation between CD44v6 expression and 5-year survival of patients. The 5-year survival of the high-expression group was significantly lower than that of the low-expression group (P=0.0041).
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65:87–108. doi: 10.3322/caac.21262. - DOI - PubMed
    1. Aristarco V, Serrano D, Gandini S, Johansson H, Macis D, Guerrieri-Gonzaga A, Lazzeroni M, Feroce I, Pruneri G, Pagani G, et al. A randomized, placebo-controlled, phase II, presurgical biomarker trial of celecoxib versus exemestane in postmenopausal breast cancer patients. Cancer Prev Res (Phila) 2016;9:349–356. doi: 10.1158/1940-6207.CAPR-15-0311. - DOI - PubMed
    1. Alvarado-Luna G, Morales-Espinosa D. Treatment for small cell lung cancer, where are we now? - a review. Transl Lung Cancer Res. 2016;5:26–38. - PMC - PubMed
    1. Rudin CM, Ismaila N, Hann CL, Malhotra N, Movsas B, Norris K, Pietanza MC, Ramalingam SS, Turrisi AT, III, Giaccone G. Treatment of small-cell lung cancer: American Society of Clinical Oncology Endorsement of the American College of Chest Physicians Guideline. J Clin Oncol. 2015;33:4106–4111. doi: 10.1200/JCO.2015.63.7918. - DOI - PubMed
    1. Hanagiri T, Oka S, Takenaka S, Baba T, Yasuda M, Ono K, So T, Uramoto H, Takenoyama M, Yasumoto K. Results of surgical resection for patients with large cell carcinoma of the lung. Int J Surg. 2010;8:391–394. doi: 10.1016/j.ijsu.2010.06.003. - DOI - PubMed